Kasetsuwan N, Suwajanakorn D, Tantipat C, et al. - Researchers conducted this randomized controlled trial to assess the effectiveness of additional thermal pulsatile system compared with standard lid hygiene alone in meibomian gland dysfunction (MGD) patients who are using long-term anti-glaucoma medications. Well-controlled glaucoma patients who had been using anti-glaucoma drugs for at least 1 year and had MGD were recruited and randomized between the study group receiving thermal pulsatile system (Lipiflow®) treatment and standard lid hygiene, and a control group receiving standard lid hygiene alone. Of 60 candidates who underwent randomization, 48 finished the study. An additional single thermal pulsatile system treatment with standard lid hygiene substantially increased meibomian gland assessment score and subjective symptoms at 6 months. There was no difference between additional thermal pulsatile system treatment and lid hygiene alone in this research. Results may indicate more chronic MGD and more damaged meibomian gland caused by long-term anti-glaucoma drugs.